Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8826215 | 0.98 | PDE7B (0.33) | PDE7BKDM4E | |
| SCHEMBL31387388 | 0.95 | — | — | |
| SCHEMBL26627545 | 0.90 | — | — | |
| SCHEMBL20396134 | 0.79 | NEK2 (0.32) | — | |
| SCHEMBL26444546 | 0.78 | — | — | |
| SCHEMBL614887 | 0.76 | — | — | |
| SCHEMBL27096715 | 0.75 | — | — | |
| SCHEMBL12542094 | 0.75 | ALDH1A1 (0.31) | KDM4E | |
| SCHEMBL28272317 | 0.75 | TRIM24 (0.32) | — | |
| SCHEMBL19693619 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9849119-B2 | Opioid receptor ligands and methods of using and making same | TREVENA, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-9849119-B2 | Opioid receptor ligands and methods of using and making same | TREVENA, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20170326124-A1 | Opioid Receptor Ligands And Methods Of Using And Making Same | TREVENA, INC. | 2017-11-16 | — | — | US | disclosed |
| US-9642842-B2 | Opioid receptor ligands and methods of using and making same | Trevana, Inc. (US) | 2017-05-09 | — | — | US | disclosed |
| US-9642842-B2 | Opioid receptor ligands and methods of using and making same | Trevana, Inc. (US) | 2017-05-09 | — | — | US | disclosed |
| US-20160250199-A1 | Opioid Receptor Ligands And Methods Of Using And Making Same | TREVENA, INC. | 2016-09-01 | — | — | US | disclosed |
| US-9309234-B2 | Opioid receptor ligands and methods of using and making same | TREVENA, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-20150246904-A1 | Opioid Receptor Ligands And Methods Of Using And Making Same | TREVENA, INC. | 2015-09-03 | — | — | US | disclosed |
| US-9044469-B2 | Opioid receptor ligands and methods of using and making same | TREVENA, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-8835488-B2 | Opioid receptor ligands and methods of using and making same | TREVENA, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-20120245181-A1 | OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING SAME | TREVENA, INC. (US) | 2012-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160250199-A1 | Opioid Receptor Ligands And Methods Of Using And Making Same | OPRL1, OPRK1, OPRM1 | PDE7B 1532/4885KDM4E 4277/4885 |
| US-20170326124-A1 | Opioid Receptor Ligands And Methods Of Using And Making Same | OPRL1, OPRK1, OPRM1 | PDE7B 1532/4885KDM4E 4277/4885 |
| US-20120245181-A1 | OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING SAME | OPRL1, OPRK1, OPRM1 | PDE7B 1532/4885KDM4E 4277/4885 |
| US-20150246904-A1 | Opioid Receptor Ligands And Methods Of Using And Making Same | OPRL1, OPRK1, OPRM1 | PDE7B 1532/4885KDM4E 4277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.